证券代码：835670 证券简称：数字人 公告编号：2025-008 山东数字人科技股份有限公司 第三届董事会第二十三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 27 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出董事会会议通知的时间和方式：2025 年 4 月 11 日以电话、即时通讯 方式发出 5.会议主持人：徐以发 6.会议列席人员：监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》等有关规定。 具 体 内容 详 见公 司于 2025 年 4 月 29 日 在 北京 证 券交 易所 官 网 （http://www.bse.cn）上披露的《2024 年年度报告》（公告编号：2025-010） 1 及《2024 年年度报告摘要》（公告编号：2025-011）。 2.议案表决结果：同意 9 票；反对 0 票；弃权 0 票。 ...

证券代码：835670 证券简称：数字人 公告编号：2025-022 山东数字人科技股份有限公司 关于股票可能被实施退市风险警示的风险提示公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 重要内容提示： 根据《北京证券交易所股票上市规则》第 10.4.2 条第(六)项规定,上市公 司出现"首个会计年度财务报告内部控制被出具无法表示意见或否定意见的审 计报告，或者未按照规定披露财务报告内部控制审计报告"的情形，上市公司 应当立即披露股票交易可能被实施退市风险警示的风险提示公告，并且应当至 1 少每月披露一次进展情况及风险提示公告，直至相应情形消除或公司股票被北 京证券交易所实施退市风险警示。 根据《北京证券交易所股票上市规则》第 10.4.1 条第(六)项规定，上市 公司出现"连续两个会计年度财务报告内部控制被出具无法表示意见或否定意 见的审计报告，或者未按照规定披露财务报告内部控制审计报告"的情形，北 京证券交易所对公司股票交易实施退市风险警示。 如公司 2025 年度出现上述情形的, 北京证券交易 ...

Financial Performance - Operating revenue for the first quarter of 2025 reached CNY 11,759,217.16, representing a significant increase of 180.25% year-over-year[11] - Net profit attributable to shareholders for the first quarter of 2025 was a loss of CNY 2,675,522.31, a decline of 431.11% compared to the same period last year[11] - The company reported a total comprehensive income of -¥2,275,518.95 for Q1 2025, compared to ¥1,812,845.94 in Q1 2024, reflecting a substantial decline[42] - The net profit for Q1 2025 was a loss of ¥2,275,518.95, compared to a net profit of ¥1,812,845.94 in Q1 2024, indicating a decline in profitability[41] - Basic and diluted earnings per share for Q1 2025 were both -¥0.03, compared to ¥0.01 in Q1 2024[40] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY 11,351,613.64, a decrease of 767.99% year-over-year[11] - The net cash flow from operating activities for Q1 2025 was negative at -¥11,351,613.64, compared to -¥1,307,802.31 in Q1 2024, showing a worsening cash flow situation[43] - The cash inflow from operating activities totaled ¥24,124,572.78 in Q1 2025, slightly up from ¥23,702,145.00 in Q1 2024, showing a marginal improvement[43] - Cash and cash equivalents decreased by 37.27% to CNY 99,740,270.63 due to investments in short-term low-risk financial products[12] - The total cash and cash equivalents at the end of Q1 2025 were ¥95,627,247.85, down from ¥132,492,935.82 at the end of Q1 2024, a decrease of approximately 28%[43] Assets and Liabilities - Total assets as of March 31, 2025, were CNY 271,577,014.77, a decrease of 0.18% compared to the end of 2024[11] - Total liabilities as of March 31, 2025, were CNY 32,843,353.36, up from CNY 30,661,896.67 at the end of 2024, indicating an increase of approximately 7.12%[34] - The company's equity decreased from CNY 241,409,183.72 to CNY 238,733,661.41, a decline of about 0.70%[34] - Current assets totaled CNY 201,147,518.77, compared to CNY 202,914,844.59 at the end of 2024, indicating a decrease of approximately 0.87%[32] - Total liabilities decreased to ¥26,472,343.63 from ¥27,448,362.32, indicating a reduction in financial obligations[37] Investments and Expenses - Total operating costs for Q1 2025 were ¥16,512,097.75, up from ¥13,490,042.27 in Q1 2024, reflecting a rise in expenses[38] - Research and development expenses for Q1 2025 were ¥6,080,548.20, compared to ¥5,438,823.06 in Q1 2024, highlighting an increase in investment in innovation[38] - The company incurred total operating expenses of ¥35,476,186.42 in Q1 2025, compared to ¥25,009,947.31 in Q1 2024, marking an increase of about 41.9%[43] Shareholder Information - The total number of unrestricted shares increased from 66,328,421 to 66,648,421, representing a rise from 62.47% to 62.77% of total shares[19] - Major shareholder Xu Yifa holds 43,378,037 shares, accounting for 40.85% of total shares, with 32,533,528 being unrestricted[20] - The total share capital remained unchanged at 106,182,400 shares, with 9,127 shareholders[19] Legal Matters - The company initiated legal proceedings against Yichang Chengfa Kangyang Industry Investment Co., Ltd. for unpaid goods totaling 5,334,725.00[25] - The company also filed a lawsuit against Wuhan Jinmao Engineering Technology Co., Ltd. for the return of unjust enrichment amounting to 5,214,627.00[26] Other Financial Metrics - Non-recurring gains totaled 587,942.58, significantly impacting the financial results[17] - The company reported a credit impairment loss of ¥493,360.88 for Q1 2025, compared to ¥2,844,726.63 in the previous year, indicating improved asset quality[39] - The company recorded a fair value change gain of ¥134,711.27 in Q1 2025, contributing positively to the financial results[39]

Company Performance - The company's operating revenue for 2024 was ¥66,341,007.26, a decrease of 31.31% compared to ¥96,578,667.69 in 2023[28]. - The net profit attributable to shareholders was -¥4,159,237.26, representing a decline of 135.74% from ¥11,638,296.15 in the previous year[28]. - The gross profit margin improved to 72.23% in 2024, up from 68.49% in 2023[28]. - Total assets decreased by 1.72% to ¥272,071,080.39 from ¥276,828,764.33 at the end of 2023[30]. - Total liabilities increased by 23.19% to ¥30,661,896.67 compared to ¥24,889,399.35 at the end of 2023[30]. - The net asset attributable to shareholders decreased by 4.18% to ¥241,409,183.72 from ¥251,939,364.98 in 2023[30]. - The operating cash flow for 2024 was ¥28,859,827.45, down 9.95% from ¥32,050,406.98 in 2023[30]. - The company reported a basic earnings per share of -¥0.04, a decrease of 136.36% from ¥0.11 in 2023[28]. - The revenue for the fourth quarter (October-December) was ¥37,885,326.57, contributing significantly to the annual total[35]. Research and Development - The company holds 17 invention patents and 72 copyrights, with over 20% of revenue invested in R&D in recent years[53]. - The company's R&D expenses increased by 2.30% to 23.47 million yuan, representing 35.38% of total revenue in 2024[82]. - The total number of R&D personnel increased to 125, with the proportion of R&D staff to total employees rising to 51.65%[110]. - The company is currently developing a high-definition digital human project aimed at enhancing clinical medical product development and increasing market share[112]. - A virtual reality training project for clinical anesthesia is in development, addressing the significant talent gap in anesthesiology in China[113]. - The company is working on a cell-level 3D reconstruction system that aims to visualize microanatomical structures, significantly changing disease structure research methods[116]. - The digital human anatomy system is being upgraded based on the latest digital human data to enhance its functionality and competitiveness in the digital anatomy field[117]. - The company is collaborating with universities to obtain high-definition human imaging data for its projects, enhancing its research capabilities[112]. Market Presence and Strategy - The company has established a market presence in over 500 medical institutions nationwide and has initiated pilot sales in over 40 countries[46]. - The company plans to expand its business from medical education to clinical medicine and public health[53]. - The company aims to enhance its core competitiveness and expand market applications through a dual-driven development model of "data accumulation" and "technological innovation"[147]. - By 2025, the company plans to maintain a leading market share with a focus on "application-oriented" strategies, including the promotion of virtual anatomy laboratories and the integration of AI in curriculum development[148]. - The company is committed to corporate social responsibility by providing quality products and services, ensuring employee rights, and contributing to humanitarian efforts[130]. Financial Management and Audit - The company has appointed Xinyong Zhonghe Accounting Firm as its auditor, which issued a qualified audit opinion for the financial report[14]. - The audit report issued by the accounting firm includes a qualified opinion due to the inability to obtain sufficient audit evidence regarding the recognition of accounts receivable[122]. - The company will implement measures to strengthen internal controls and compliance checks to mitigate operational risks and protect shareholder interests[124]. - The company has received a high-tech enterprise certificate, allowing it to enjoy a reduced corporate income tax rate of 15% for the year 2024[105]. - The company plans to enhance accounts receivable management by refining customer credit assessment and collection processes to ensure timely and secure cash flow[124]. Innovation and Technology Integration - The company is focused on integrating technology and service to enhance brand recognition and market competitiveness[64]. - The company aims to leverage advanced technologies like virtual reality and artificial intelligence to enhance digital education resources[59]. - The company is committed to integrating AI and multi-modal technologies into product development to enhance educational outcomes[45]. - The company is leveraging innovative technologies such as VR/AR to enhance its educational offerings and expand its market presence[114]. Challenges and Risks - The company faces risks from potential changes in national policies that could impact the medical informationization industry, which it plans to mitigate by closely tracking policy developments[151]. - Increased market competition is anticipated, prompting the company to enhance R&D investments and maintain product leadership through innovation and collaboration[152]. - The company recognizes the risk of not accurately grasping industry trends and plans to strengthen product development and sales efforts to counteract potential negative impacts[152]. - The company has identified significant uncertainty regarding the recoverability of accounts receivable over one year old, leading to the estimation of bad debt provisions[123]. Corporate Governance and Management - The company is committed to improving its financial management system, enhancing accounting information quality, and establishing effective internal control and risk prevention mechanisms[67]. - The board of directors is committed to enhancing corporate governance and internal control processes to eliminate risks and promote healthy development[162]. - The company continues to focus on expanding its management team with experienced professionals from diverse backgrounds[199]. - The company is actively managing its leadership transitions to ensure continuity and stability in its operations[198].

"太便捷了，150多万元款项'秒到'，跨境支付成功！"回忆起不久前的一笔支付业务，西安某进出口企业 负责人的激动之情溢于言表。在人民银行陕西省分行的指导下，交通银行陕西省分行近日为这家进出口公司 成功办理一笔多边央行数字货币桥人民币香港跨境支付业务，汇款金额150.78万元——该笔业务是陕西省内 首笔央行数字货币桥业务，也是对数字人民币在西安市创新运用的生动注脚。 数字人民币是汇聚数字金融力量，助推中国式现代化建设的重要支撑，是中国数字经济时代的"新基 建"之一。记者从西安市委金融办了解到，我市近年来稳妥有序开展数字人民币试点工作，不断夯实受理环 境，聚焦数字政务、智慧城市、文化旅游、乡村振兴、普惠金融等领域，推动数字人民币实现从"尝鲜"走 向"常用"，为市民和企业提供了更加便捷、安全、高效的支付环境。截至目前，西安地区支持数字人民币支 付商店门户数累计81.65万个，数字人民币消费金额累计9.85亿元、共1636万笔。 数字政务 解锁高效服务新密码 在数字政务领域，数字人民币的应用为企业和市民提供了更加高效的政务服务。 记者从西安市委金融办相关处室了解到，我市已陆续实现了政策奖补资金发放、税费同步征收、社会 ...

在以AIGC(人工智能生成内容,Artificial Intelligence Generated Content)、大数据分析、数字孪生等为代表 的创新技术蓬勃发展的背景下，数字人(Digital Human)正在数字化转型赋能舞台上向大家展现出它的独 特魅力与潜能。 目前，集团旗下相关产品及解决方案拥有良好的自然语言处理与机器学习能力，支持多语种沟通和多模 态精准识别与可靠扩展。在实际应用中，该类产品及解决方案可依据所服务行业客户的具体需求与场景 属性进行高适配性调整与优化，流畅实现在具体应用中多系统间的准确切换、设备控制、数据导出、智 能化评估、环节监控等一系列数字化操作与实时信息交互。与此同时，在数字化应用价值方面，该类产 品及解决方案可为行业客户提供更便捷、更个性化的服务，为所服务行业客户在用户体验改善、服务效 率提升、运营成本降低、推广业务场景和服务模式创新等诸多方面带来更直观的价值呈现。 后续，新纽科技将深耕技术创新的同时，积极探索帮助行业客户实现数字化及数智化转型赋能高质量发 展的更多可能，努力为以数字人为代表的创新应用，在更广泛行业领域与业务场景中的落地开花提 供"土壤"与"养分"。 新纽科 ...

证券代码：835670 证券简称：数字人 公告编号：2025-033 山东数字人科技股份有限公司 关于召开 2024 年年度股东会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东会届次 本次会议为 2024 年年度股东会。 （二）召集人 本次股东会的召集人为董事会。 （三）会议召开的合法性、合规性 本次股东会的召集、召开、议案审议程序符合《公司法》和《公司章程》 的有关规定。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 公司同一股东应选择现场投票或网络投票中的一种，如果同一表决权出现 重复投票表决的，以第一次投票表决结果为准。 （五）会议召开日期和时间 登记在册的股东可通过中国证券登记结算有限责任公司（以下简称"中国结 算"）持有人大会网络投票系统对有关议案进行投票表决，为有利于投票意见的 顺利提交，请拟参加网络投票的投资者在上述时间内及早登录中国结算网上营业 1 厅（网址：inv.chinaclear.cn）或关注中国结 ...

证券代码：835670 证券简称：数字人 公告编号：2025-027 山东数字人科技股份有限公司 董事会关于 2024 年度财务报表审计出具非标准审计意见报 告的专项说明 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 信永中和会计师事务所（特殊普通合伙）接受山东数字人科技股份有限公 司（以下简称"公司"）委托，对公司2024年度财务报表进行审计，并出具了 保留意见的审计报告。根据《公开发行证券的公司信息披露编报规则第14号— —非标准审计意见及其涉及事项的处理》《北京证券交易所股票上市规则》等 有关规定，公司董事会对该审计报告涉及事项作出如下说明 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的 "注册会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的 责任。按照中国注册会计师职业道德守则，我们独立于数字人公司，并履行了 职业道德方面的其他责任。我们相信，我们获取的审计证据是充分、适当的， 为发表保留意见提供了基础。 上述事项可能对财务报表产生的影响重大但是不具有广泛性，我们 ...

证券代码：835670 证券简称：数字人 公告编号：2025-021 山东数字人科技股份有限公司 董事会审计委员对会计师事务所履行监督职责情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 二、会计师事务所履职情况 1 信永中和对公司 2024 年度财务报告进行了审计，同时对公司内部控制执行 情况、募集资金存放与实际使用情况、非经营性资金占用及其他关联资金往来 情况、2024 年度营业收入扣除情况的专项说明等进行核查并出具了相关报告或 专项说明。 在执行审计工作的过程中，公司董事会审计委员与信永中和会计师进行事 前充分沟通，信永中和会计师事务所和相关审计人员的独立性、审计工作小组 的人员构成、审计计划、风险判断的测试和评价方法、年度审计重点、审计调 整事项、初审意见等与公司治理层进行了沟通，有效的提升了工作的准确性。 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《国有企业、 上市公司选聘会计师事务所管理办法》等规定和要求，山东数字人科技股份有 限公司（以下简称"公司"）董事会审计委员会 ...

国投证券股份有限公司 关于山东数字人科技股份有限公司 2024 年度募集资金存放与实际使用情况的专项核查报告 山东数字人科技股份有限公司（以下简称"数字人"或"公司"）股票于 2020 年 12 月 8 日在全国中小企业股份转让系统精选层挂牌，并于 2021 年 11 月 15 日 平移至北京证券交易所上市。国投证券股份有限公司（以下简称"国投证券"或 "保荐机构"）作为数字人向不特定合格投资者公开发行股票并在精选层挂牌（以 下简称"本次发行"）的保荐机构，履行持续督导职责期限至 2023 年 12 月 31 日。 因数字人本次发行募集资金尚未使用完毕，保荐机构继续履行对公司剩余募集资 金管理及使用事项的持续督导责任。 根据《北京证券交易所股票上市规则》《北京证券交易所上市公司持续监管 办法（试行）》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求（2022 年修订）》等相关规定，保荐机构对数字人 2024 年度的募集资金 存放与实际使用情况进行了核查，并出具本专项核查报告。 一、募集资金的基本情况 （一）实际募集资金金额和资金到账时间 中国证券监督管理委员会于 2020 年 9 月 2 ...